H.C. Wainwright initiates coverage of Mink Therapeutics with Buy rating
H.C. Wainwright assumed coverage of Mink Therapeutics with a Buy rating and a $38 price target.
Related stories
Lyell Immunopharma Announces $80M Private Placement
Lyell Immunopharma says the private placement will advance Ronde-Cel toward a planned BLA submission.
M impact | EQUITY | Nov 04, 2026, 02:09 PM UTC
Spartan Delta Reports Q3 Results, Raises 2026 Capital Plan and Sets 2027 Guidance
Third-quarter Adjusted Funds Flow was $109.5 million, up 117% year over year, on production of 53,448 BOE/d and record 46% liquids weighting. Spartan raised its 2026 capital progra
M impact | EQUITY | Nov 04, 2026, 02:02 PM UTC
European session market picture: S&P 500 +1.17%, Nasdaq 100 +0.35%; EUR/USD +0.63%, WTI -2.92%, LLOY leads volume
European session market picture. US index futures: S and P futures is up 1.17 percent, Nasdaq futures is up 0.35 percent, Dow futures is up 2.22 percent and Russell futures is up 1
M impact | EQUITY | Nov 04, 2026, 02:02 PM UTC
Dolphin to Host Q3 2026 Earnings Call on November 10
Dolphin said it will host its third-quarter 2026 earnings conference call on November 10, 2026.
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC
Immunome Reports 53% ORR in 19 B-NHL Patients
At the June 26, 2026 interim cutoff, 10 of 19 response-evaluable B-NHL patients had an overall response, including five complete and five partial responses. In the 11-patient DLBCL
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC
SM Energy Reports Third-Quarter Revenue of $2.17 Billion
Third-quarter net income was $93 million and diluted EPS was $0.39, compared with $155 million and $1.35 a year earlier. Production averaged 433.1 MBOE per day, down 2% sequentiall
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC